Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMCGFY6)

Drug Name

KOS-1815 Drug Info

Synonyms

CRM1 and nuclear export inhibitors (cancer); KOS-2385; KOS-2464; CRM1 and nuclear export inhibitors (cancer), Kosan

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Preclinical	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Exportin-1 (XPO1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Selinexor	DMBD4K3	Multiple myeloma	2A83	Phase 3	[2]
Selinexor oral	DMDLOBZ	Recurrent glioblastoma	2A00.00	Phase 2	[3]
Eltanexor oral	DM7CLEZ	Colorectal cancer	2B91.Z	Phase 1/2	[4]
SL-801	DMIVGYK	Solid tumour/cancer	2A00-2F9Z	Phase 1	[4]
S109	DM2JYQA	Solid tumour/cancer	2A00-2F9Z	Investigative	[5]
Octahydrocurcumin	DMUFDR6	Solid tumour/cancer	2A00-2F9Z	Investigative	[6]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024269)
2	Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agents. Semin Cancer Biol. 2014 August; 0: 62-73.
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5	Reversible inhibitor of CRM1 sensitizes glioblastoma cells to radiation by blocking the NF-B signaling pathway. Cancer Cell Int. 2020 Mar 30;20:97.
6	Therapeutic strategies targeting FOXO transcription factors. Nat Rev Drug Discov. 2021 Jan;20(1):21-38.